gammaCore®-Sapphire迷走神经刺激治疗中重度COVID-19呼吸症状的前瞻性随机对照试验方案摘要
SAVIOR试验为单中心、2臂、前瞻性、1:1随机对照试验,评估gammaCore®-Sapphire迷走神经刺激联合标准治疗对比单纯标准治疗,能否降低中重度COVID-19患者机械通气依赖。计划入组90例(每组45例),主要终点为随机至ICU或出院期间启动机械通气,次要终点包括细胞因子趋势、氧需求、死亡率等。
要点
- gammaCore®-Sapphire迷走神经刺激联合标准治疗可能降低中重度COVID-19患者机械通气需求。
- 试验计划入组90例,随机1:1分组,分层因素为性别和年龄。
- 主要终点为随机至ICU或出院期间启动机械通气。
核心结论
- 该研究旨在评估gammaCore®-Sapphire迷走神经刺激联合标准治疗能否减少中重度COVID-19患者的机械通气依赖。
研究设计与样本
- 单中心、2臂、前瞻性、1:1随机、平行对照试验,比较gammaCore®-Sapphire联合标准治疗与单纯标准治疗。
- 计划入组90例中重度COVID-19患者,每组45例。
- 随机按氧合水平分层为轻、中、重度,并进一步按性别和年龄分层。
- 开放标签设计,参与者和医护人员无法设盲。
- 研究对象来自西班牙瓦伦西亚大学临床医院。
关键数值与推荐
- 主要终点:随机至ICU入院或出院(以先发生者为准)期间启动机械通气。
- 次要终点包括安全性(不良事件/严重不良事件)、细胞因子风暴(TNF-α、IL-6、IL-1β,第1、3、5、10、15天和/或出院时)、死亡率和/或重症监护入院需求、氧饱和度水平、补充氧需求。
- 纳入标准:年龄>18岁,COVID-19检测阳性或疑似/推测阳性,有咳嗽、气短或呼吸室内空气氧饱和度≤92%且无需机械通气或急性呼吸衰竭。
- 干预方案:预防性给药为每天三次(早晨、中午、睡前1小时)每次颈部两侧各2分钟;急性呼吸衰竭或气短时颈部两侧各2分钟,若20分钟后气短持续则追加一次,每日最大剂量为9次或18次刺激。
- 对照组接受标准治疗,包括氧疗、抗生素和必要时的通气支持。
临床怎么用
- 该方案为研究阶段,结果尚未报告,临床实践应遵循现行COVID-19治疗指南。
局限性
- 单中心研究可能限制结果外推性。
- 开放标签设计可能引入偏倚。
- 计划样本量较小(90例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary Objective: The primary objective is to reduce initiation of mechanical ventilator dependency in patients with moderate to severe CoViD- 19. This will be measured as the difference between the control group and active group for subjects admitted to the hospital for CoViD-19. Secondary Objectives: • To evaluate cytokine trends / Prevent cytokine storms • To evaluate supplemental oxygen requirements • To decrease mortality of CoViD-19 patients • Delay onset of ventilation TRIAL DESIGN: The study is a single centre, 2-arm, prospective, randomized (ratio 1:1), controlled trial with parallel groups design to compare the reduction of respiratory distress in a CoViD-19 population, using the intervention of the gammaCore®-Sapphire device plus standard of care (active) vs. standard of care alone (SoC) - the control group. The gammaCore® treatments will be used acutely and prophylactically. The active and control groups will be matched for disease and severity. PARTICIPANTS: i. Inclusion Criteria The subjects have to meet all of the following criteria to be eligible to enter the trial: 1.Patient older than 18 years2.Been tested positive or suspected/presumed positive for CoViD-19 Has a cough, shortness of breath or respiratory O2 Saturation less than or equal to 92% without need for mechanical ventilation or acute respiratory failure 3.Agree to use the gammaCore®-Sapphire device as intended and to follow all of the requirements of the study including recording required study data4.Patient is able to provide signed and witnessed Informed Consent ii. Exclusion Criteria Subjects meeting any of the following criteria cannot be included in this research study: 1.Pregnant women2.On home/therapy oxygen (i.e. for patients with Chronic Obstructive Pulmonary Disease) at baseline prior to development of CoViD-193.Patient already enrolled in a clinical trial using immunotherapeutic regimen for CoViD-194.History of aneurysm, intracranial hemorrhage, brain tumors, or significant head trauma5.Known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (eg, bruits or history of transient ischemic attack or cerebrovascular accident), congestive heart failure, known severe coronary artery disease, or recent myocardial infarction6.Uncontrolled high blood pressure (>140/90)7.Current implantation of an electrical and/or neurostimulator device, including but not limited to a cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant8.Current implantation of metal cervical spine hardware or a metallic implant near the gammaCore stimulation site9.Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g. homeless, developmentally disabled and prisoner) Participants will be recruited from Hospital Clínico Universitario de Valencia in Spain. INTERVENTION AND COMPARATOR: Intervention: Prophylactic: Administer 2 doses (at 2 minutes each) of gammaCore®-Sapphire, one dose on each side of the neck scheduled three times a day (morning, mid-day and 1 hour before bed at night).Acute respiratory failure or shortness of breath: Administer 2 doses (at 2 minutes each) of gammaCore®-Sapphire, one on each side of the neck. If shortness of breath (SOB) persists 20 minutes after the start of the first treatment, a second dose will be administered. Max doses per day is 9 or 18 stimulations.Plus standard of care Control: Standard of care: oxygen therapy, antibiotics and ventilatory support if necessary depending on the clinic MAIN OUTCOMES: Primary Endpoint: Initiation of mechanical ventilation, from randomization until ICU admission or hospital discharge, whatever occurs first Secondary Endpoints: Safety; ascertainment of Adverse Effects/Serious Adverse Events, from randomisation to ICU admission or hospital discharge, whatever occurs firstCytokine Storm measured by: Tumor necrosis factor α, Interleukin 6, Interleukin 1β. Days 1,3,5,10,15 and/or at hospital dischargeMortality and/or need for Critical Care admission, from randomisation until ICU admission or hospital discharge, whatever occurs first,O2 saturation levels , from randomization until ICU admission or hospital discharge, whatever occurs firstNeed for supplemental oxygen, from randomisation until ICU admission or hospital discharge, whatever occurs first RANDOMISATION: The patients are classified according to their oxygen levels as mild, moderate and severe and randomized according to their classification to the intervention and control in a ratio of 1:1. The randomization will be stratified for gender and age. BLINDING (MASKING): This is an open label study, it is not possible to blind the participants and healthcare providers to the intervention. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The total number of patients to be included in the study is 90, with 45 in each study group TRIAL STATUS: The protocol version is 8.0 from 07th April 2020. The recruitment began 20th April 2020 and is expected to be complete 31st July 2020. TRIAL REGISTRATION: The study is registered in clinicaltrials.gov on 29th April 2020 with the identification number: NCT04368156 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Tornero C, Vallejo R, Cedeño D, et al. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial". Trials. 2020. PMID: 32586395. doi:10.1186/s13063-020-04486-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。